Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
NCT ID: NCT00235508
Last Updated: 2012-02-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
420 participants
INTERVENTIONAL
2005-06-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients
NCT00460993
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
NCT00352144
Eszopiclone Treatment & Cortisol Responsivity
NCT00889200
The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women
NCT00374192
Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability
NCT00368056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Escitalopram oxalate 10 mg at bedtime
Eszopiclone (Lunesta)
Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
2
Eszopiclone 3 mg at bedtime
Eszopiclone (Lunesta)
Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eszopiclone (Lunesta)
Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with Generalized Anxiety Disorder (GAD)
* Subjects with insomnia related to GAD.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wichita Falls, Texas, United States
Falls Church, Virginia, United States
Richmond, Virginia, United States
Middleton, Wisconsin, United States
Birmingham, Alabama, United States
Mesa, Arizona, United States
Scottsdale, Arizona, United States
Irvine, California, United States
La Mesa, California, United States
National City, California, United States
Oceanside, California, United States
Orange, California, United States
Pasadena, California, United States
Redlands, California, United States
Riverside, California, United States
San Diego, California, United States
Farmington, Connecticut, United States
Washington D.C., District of Columbia, United States
Coral Springs, Florida, United States
Fort Lauderdale, Florida, United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Pembroke Pines, Florida, United States
St. Petersburg, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Smyrna, Georgia, United States
Northfield, Illinois, United States
Indianapolis, Indiana, United States
Owensboro, Kentucky, United States
Baltimore, Maryland, United States
Rockville, Maryland, United States
Braintree, Massachusetts, United States
Brighton, Massachusetts, United States
Brockton, Massachusetts, United States
Cambridge, Massachusetts, United States
Watertown, Massachusetts, United States
St Louis, Missouri, United States
Kenilworth, New Jersey, United States
Piscataway, New Jersey, United States
Brooklyn, New York, United States
Lawrence, New York, United States
New York, New York, United States
Durham, North Carolina, United States
Raleigh, North Carolina, United States
Winston-Salem, North Carolina, United States
Bismarck, North Dakota, United States
Beachwood, Ohio, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Middleburg Heights, Ohio, United States
Eugene, Oregon, United States
Portland, Oregon, United States
Salem, Oregon, United States
Moon Township, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Scotland, Pennsylvania, United States
Columbia, South Carolina, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Houston, Texas, United States
Richardson, Texas, United States
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011 Apr;72(4):473-9. doi: 10.4088/JCP.09m05131gry. Epub 2010 Nov 2.
Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008 May;65(5):551-62. doi: 10.1001/archpsyc.65.5.551.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
190-902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.